Imunon (NASDAQ:IMNN – Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Imunon to post earnings of ($0.36) per share for the quarter.
Imunon Trading Up 5.4 %
Shares of IMNN opened at $0.92 on Friday. Imunon has a twelve month low of $0.53 and a twelve month high of $3.65. The stock’s 50 day moving average is $0.89 and its two-hundred day moving average is $0.96. The firm has a market capitalization of $13.33 million, a PE ratio of -0.49 and a beta of 2.03.
Analyst Ratings Changes
A number of brokerages have weighed in on IMNN. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Imunon in a report on Thursday, December 19th. D. Boral Capital reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Imunon in a report on Wednesday.
About Imunon
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Featured Stories
- Five stocks we like better than Imunon
- The How And Why of Investing in Oil Stocks
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- What Are Dividend Challengers?
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- What Does Downgrade Mean in Investing?
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
